Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has earned a consensus recommendation of “Hold” from the twenty-six analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, sixteen have given a hold rating, six have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $407.13.
A number of equities analysts recently weighed in on REGN shares. TheStreet raised shares of Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, January 17th. Guggenheim raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $461.00 price target on the stock in a report on Friday, January 4th. Cowen reaffirmed a “hold” rating and set a $385.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, January 7th. Goldman Sachs Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “conviction-buy” rating in a report on Thursday, December 13th. Finally, Oppenheimer set a $440.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, December 2nd.
Shares of NASDAQ:REGN traded up $8.66 during midday trading on Friday, reaching $439.40. The company had a trading volume of 21,202 shares, compared to its average volume of 703,605. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47. The company has a market capitalization of $46.96 billion, a P/E ratio of 22.17, a price-to-earnings-growth ratio of 1.68 and a beta of 1.27. Regeneron Pharmaceuticals has a 52-week low of $281.89 and a 52-week high of $434.35.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share for the quarter, topping the Zacks’ consensus estimate of $5.10 by $1.74. The company had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.73 billion. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The firm’s quarterly revenue was up 21.9% on a year-over-year basis. During the same period in the previous year, the firm earned $5.23 EPS. As a group, research analysts predict that Regeneron Pharmaceuticals will post 19.92 earnings per share for the current year.
In other news, Director Joseph L. Goldstein sold 1,791 shares of the company’s stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $410.00, for a total transaction of $734,310.00. Following the sale, the director now directly owns 14,114 shares in the company, valued at $5,786,740. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Christopher R. Fenimore sold 1,848 shares of the company’s stock in a transaction dated Thursday, December 20th. The shares were sold at an average price of $358.97, for a total value of $663,376.56. Following the sale, the vice president now owns 9,871 shares in the company, valued at $3,543,392.87. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,645 shares of company stock worth $1,399,980. Company insiders own 12.42% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Capital International Investors bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $703,075,000. FMR LLC increased its position in shares of Regeneron Pharmaceuticals by 17.0% in the third quarter. FMR LLC now owns 5,016,501 shares of the biopharmaceutical company’s stock worth $2,026,867,000 after purchasing an additional 728,104 shares during the last quarter. Capital World Investors increased its position in shares of Regeneron Pharmaceuticals by 5.3% in the third quarter. Capital World Investors now owns 6,384,323 shares of the biopharmaceutical company’s stock worth $2,579,522,000 after purchasing an additional 322,051 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of Regeneron Pharmaceuticals by 35.8% in the third quarter. Alliancebernstein L.P. now owns 1,023,594 shares of the biopharmaceutical company’s stock worth $413,573,000 after purchasing an additional 269,696 shares during the last quarter. Finally, Ffcm LLC increased its position in shares of Regeneron Pharmaceuticals by 27,119.4% in the third quarter. Ffcm LLC now owns 256,407 shares of the biopharmaceutical company’s stock worth $11,599,000 after purchasing an additional 255,465 shares during the last quarter. Hedge funds and other institutional investors own 66.52% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: Balance Sheet